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Langerhans Cells Release Prostaglandin D2 in
Response to Nicotinic Acid
Dominique Maciejewski-Lenoir1, Jeremy G. Richman1, Yaron Hakak1, Ibragim Gaidarov1,
Dominic P. Behan1 and Daniel T. Connolly1
Nicotinic acid, used for atherosclerosis treatment, has an adverse effect of skin flushing. The flushing
mechanism, thought to be caused by the release of prostaglandin D2 (PGD2), is not well understood. We aimed
to identify which cells mediate the flushing effect. Nicotinic acid receptor (GPR109A) gene expression was
assessed in various tissues and cell lines. Cells expressing GPR109A mRNA were further assayed for PGD2
release in response to nicotinic acid. Of all samples, only skin was able to release PGD2 upon stimulation with
nicotinic acid. The responsive cells were localized to the epidermis, and immunocytochemical studies revealed
the presence of GPR109A on epidermal Langerhans cells. CD34þ cells isolated from human blood and
differentiated into Langerhans cells (hLC-L) also showed GPR109A expression. IFNg treatment increased both
mRNA and plasma membrane expression of GPR109A. IFNg-stimulated hLC-Ls released PGD2 in response to
nicotinic acid in a dose-dependant manner (effector concentration for half-maximum response¼ 1.2 mM70.7).
Acifran, a structurally distinct GPR109A ligand, also increased PGD2 release, whereas isonicotinic acid, a
nicotinic acid analog with low affinity for GPR109A, had no effect. These results suggest that nicotinic acid
mediates its flushing side effect by interacting with GPR109A on skin Langerhans cells, resulting in release of
PGD2.
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INTRODUCTION
Oral administration of nicotinic acid (niacin) reduces serum
low-density lipoprotein cholesterol and triglycerides, and
elevates serum high-density lipoprotein cholesterol levels,
but also elicits an intense flushing reaction in most subjects.
This often limits the use of nicotinic acid for the treatment of
dislipidemia (Carlson, 2005). Topical application of skin-
permeable nicotinic acid esters similarly causes a marked
local cutaneous vasodilatation (Winkelman et al., 1965,
Messamore, 2003). This flushing reaction can be blocked in
both cases by cyclooxygenase inhibitors, implicating pros-
taglandins in the flushing mechanism (Eklund et al., 1979).
Morrow et al. (1992) have demonstrated that the vasodilata-
tion observed after oral or topical nicotinic acid administra-
tion correlates with the release of prostaglandin D2 (PGD2)
from the skin. Immunohistochemical studies in skin showed
that hematopoietic glutathione-requiring PGD2 synthase was
abundantly expressed in Langerhans cells in the epidermis,
and to a lower extent, in macrophages, histiocytes, and mast
cells in the dermis (Ujihara et al., 1988). However, the skin
cell types responsible for the nicotinic acid response were not
determined.
A specific G-protein-coupled receptor for nicotinic acid
was first identified on membranes from adipocytes and
spleen cells (Lorenzen et al., 2001). It was further demon-
strated that the murine PUMA-G (protein upregulated in
macrophages by IFNg) and its human ortholog HM74A are
receptors for nicotinic acid (collectively called GPR109A)
and mediate its anti-lipolytic effect (Tunaru et al., 2003, Wise
et al., 2003). The nicotinic acid receptor expressed on mouse
macrophages was shown to have pharmacological properties
indistinguishable from the G-protein-coupled nicotinic acid
receptor expressed on spleen cell membranes (Lorenzen
et al., 2002). It was thus suggested that the effects of nicotinic
acid on macrophages, spleen, and adipocytes are mediated
via an identical G-protein-coupled receptor (GPR109A).
Based on the hypothesis that the flushing reaction elicited
by nicotinic acid is a GPR109A-mediated event, we selected
cells expressing this receptor for our study. To identify the
cell(s) responsible for the flushing reaction, we screened a
large set of human tissue and cells for the expression of
GPR109A, characterized them using immunocytochemistry
with antibodies (Abs) directed against GPR109A and specific
cell markers, then assayed them for PGD2 release following
nicotinic acid stimulation. This study shows that Langerhans
cells are able to specifically respond to nicotinic acid by
releasing PGD2. This PGD2 release is mediated by the
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interaction of nicotinic acid with GPR109A and is highly
regulated by IFNg.
RESULTS
GPR109A mRNA distribution in primary tissues
A panel of over 120 human tissues, primary cells, and cell
lines was analyzed by microarray analysis for the expression
of GPR109A. Figure 1 shows that GPR109A is highly
expressed in a variety of immune cell types (neutrophils,
Langerhans cells, monocytes), in the epidermoid carcinoma
cell line A-431 and in adipocytes. GPR109A was not
detected in endothelial cells, smooth muscle cells, or dermal
fibroblasts. This distribution is consistent with the report of
high expression of GPR109A in adipose tissue and spleen
(Wise et al., 2003).
GPR109A protein expression in skin
As skin was identified as a major site of PGD2 release
(Morrow et al., 1992) and a nicotinic acid reddening effect
can be directly visualized on skin using the skin flush test
(Messamore, 2003), we focused our research on skin
explants. Whole skin samples collected from both human
and mouse were separated into dermis and epidermis, and
GPR109A mRNA expression was analyzed using TaqMan
analysis. Robust expression of GPR109A was detected in the
epidermis of both species but was absent from dermal mRNA
samples (Figure 2a). Mouse skin epidermal cells were further
dissociated and cultured. Mouse GPR109A mRNA expression
was similarly analyzed in cells cultured overnight in the
presence of either 1 ng/ml GM-CSF, 100 ng/ml IFNg, both
cytokines together, or vehicle alone. Cells cultured in control
medium or medium with IFNg showed detectable but low
expression of GPR109A (Figure 2b). Cells cultured in the
presence of GM-CSF, a cytokine essential for the maturation
of Langerhans cells (Witmer-Pack et al., 1987), showed
enhanced expression of GPR109A. Cells cultured in medium
supplemented with both GM-CSF and IFNg showed a 4-fold
stimulation of mouse GPR109A mRNA expression relative to
cells grown in GM-CSF alone.
GPR109A protein expression was further examined by
Western blot analysis using lysates from cultured mouse
epidermal cells, HEK293 (human embryonic kidney) cells
transfected with GPR109A, or HEK293 cells with the vector
alone (plasmid cytomegalovirus). Figure 2c shows that anti-
GPR109-COOH Ab recognized a band of approximately
55 kDa in both mouse epidermal cells and GPR109A-
transfected HEK cells. The predicted MW of a core GPR109A
protein is 42 kDa and the higher MW band observed could
reflect post-translational modifications (e.g. glycosylation).
There was no detectable signal in cells transfected with the
vector alone.
Immunocytochemical analysis was carried out in mouse
epidermal cells to identify the cell types expressing mouse
GPR109A. Cytospin preparations from the non-adherent
fraction of mouse epidermal cells cultured in RPMI supple-
mented with GM-CSF, containing the naturally floating
Langerhans cells (Schuler and Steinman, 1985) were incu-
bated with Abs against mouse CD1, GPR109-COOH, and
cytokeratin AE3, followed by Alexa 488 or 594-conjugated
secondary Abs. A cell count of 16 different cell fields showed
that 29.875.7% of cells stained for CD1 (Figure 2d), a major
histocompatibility complex (MHC) class 1 molecule ex-
pressed by dendritic cell populations. Figure 2e shows that
anti-GPR109 immuno-positive cells appear to be the same
cell type as anti-CD1 immuno-positive cells, based on
morphological and numerical comparison of immunolabeled
cells. Double staining with anti-CD-1 and anti-GPR109-
COOH could not be done as both Abs were raised in the
rabbit; however, cells staining for GPR109 showed double
labeling with anti-MHC class II 1Ad Ab, another marker
specific to macrophages/dendritic cells (Figure 2h–j). Double
staining with both anti-keratin (green) and anti-GPR109-
COOH (red) shows no staining overlap, indicating an absence
of mouse GPR109A receptor on keratinocytes (Figure 2f).
Preincubation of GPR109-COOH Ab with a 10-fold excess of
its antigenic peptide completely inhibits fluorescence staining,
confirming that the Ab interacts with the cells specifically
through the antigen-binding site (Figure 2g).
GPR109A expression in a pure population of human Langerhans
cells
For follow-up studies, we used a commercially available pure
population of human Langerhans cells (hLC-Ls) derived from
CD34þ umbilical blood precursor cells. These cells display
hallmark features of mature Langerhans cells, including
Birbeck granules, CD1a, and MHC class II surface markers
(respectively 470 and 80% expression by FACS analysis,
personal communication by S. Ayehunie), and have been
used in three-dimensional organotypic skin models as a
surrogate for Langerhans cells (Hayden et al., 2003). The
antigenic profile of these hLC-Ls was determined using
immunocytochemistry. Cytospin preparations of hLC-Ls were
incubated with Abs against GPR109-COOH, PGD2 synthase,
or specific markers for mature hLCs (CD1a and langerin).
Figure 3 a–f show that GPR109 is expressed in over 90%
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Figure 1. Gene expression levels of GPR109A in human tissues and cell
lines. Microarray data for GPR109A were analyzed across a panel of over
100 human samples, a subset of which is shown in Figure 1. Data are the
mean7SD.
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of hLC-Ls. Fluorescence staining appears to be mostly in
intracellular compartments. The cells have veiled cytoplas-
mic extensions, are lobulated, and have eccentrically
localized nuclei characteristic of Langerhans cells (Schuler
and Steinman, 1985) (Figure 3c–f). As the anti-GPR109-
COOH Ab also recognizes GPR109B, part of the signal could
be attributed to the presence of GPR109B. The hLC-Ls
express both CD1a (Figure 3g), typically localized on the cell
surface, and langerin (Figure 3h). Finally, the hLC-Ls also
express hematopoietic PGD2 synthase (Figure 3i) showing a
distinctive punctate staining pattern. Staining with secondary
Abs alone shows only background immunofluorescence
(Figure 3j, k).
GPR109A mRNA expression in hLC-Ls was analyzed using
quantitative reverse transcriptase-PCR (RT-PCR) analysis
(Figure 4a). As observed for mouse epidermal Langerhans
cells, untreated hLC-Ls expressed low levels of GPR109A
mRNA, whereas GPR109A mRNA expression was greatly
increased with IFNg treatment. In order to determine if the
receptor protein surface expression was also increased after
IFNg treatment, vehicle and IFNg-treated cells were analyzed
by FACS (Figure 4b) and immunocytochemistry (Figure 4c)
using an anti-GPR109 Ab (Novus Biochemicals Inc., Littleton,
CO) directed against the extracellular amino-terminal do-
main. Both analyses showed a strong upregulation of GPR109
receptor on the cell surface following treatment with IFNg.
PGD2 release from cells expressing GPR109A
The mouse macrophage cell line RAW 264 was studied as
mouse macrophages were the first cells shown to express
PUMA-G, the murine ortholog of GPR109A (Schaub et al.,
2001). Although these cells were able to release PGD2 upon
stimulation with LPS or PMA, they failed to respond to
nicotinic acid at concentrations up to 50 mM, even after
100 ng/ml IFNg overnight treatment (data not shown).
Primary human cells derived from fat (GPR109A expressing
adipocytes) or skin (endothelial cells, fibroblasts, keratino-
cytes, dendritic cells) as well as A-431 epidermoid carcinoma
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Figure 2. Mouse and human GPR109A distribution in skin. (a) Quantitative RT-PCR analysis of GPR109A mRNA transcripts in dermal or epidermal tissue
isolated from mouse ear halves or human skin. (b) Quantitative RT-PCR analysis of mouse GPR109A mRNA transcripts in mouse epidermal cells cultured
overnight in RPMI supplemented as indicated. The data are expressed as relative units compared with standard amounts of mouse GPR109A DNA. (c) Western
blotting for GPR109A. Rabbit anti-GPR109-COOH polyclonal Ab immunoblotting of lysates (20 mg protein/lane) from mouse epidermal cells or HEK293 cells
transiently transfected with either GPR109A or plasmid cytomegalovirus. (d–j) Immunostaining of mouse mixed epidermal cells in culture. (d) Fluorescence
staining with anti-CD1 Abs (green) and 40,6 diamidino-2-phenylindole (DAPI) (blue). (e) Fluorescence staining with anti-GPR109-COOH Abs (green) and
DAPI (blue). (f) Double fluorescence staining with anti-cytokeratin AE3 Abs (green) and anti-GPR109-COOH Abs (red). (g) Fluorescence staining with
anti-GPR109-COOH Abs preincubated with a 10-fold molar excess of antigenic peptide and DAPI. (h) Fluorescence staining with anti-MHC class II 1Ad
(green). (i) Fluorescence staining with anti-GPR109-COOH Abs (red). (j) Double fluorescence staining with anti-MHC class II 1Ad (green) and
anti-GPR109-COOH Abs (red). Bar¼ 25 mm.
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cells were assayed for PGD2 release following nicotinic acid
stimulation. None of these cells or cell lines showed a
positive response to nicotinic acid or other stimuli (data not
shown). Similarly, whole blood, as well as neutrophils or
monocytes isolated from blood, failed to release PGD2 in
response to nicotinic acid.
PGD2 release in skin explants or cell culture
Given that skin tissue and cells were found to express
GPR109A, and that a topical application of methylnicotinate
on the skin could induce cutaneous blood flow changes
(Messamore, 2003), we sought to assess PGD2 release in ex
vivo skin explants. Whole skin punches (6 mm diameter) from
the dorsal or ventral portions of mouse ears were assayed for
nicotinic acid-stimulated PGD2 release. Figure 5a shows a
typical dose-dependent response to nicotinic acid. The skin
tissue was incubated with the indicated concentrations of
nicotinic acid for 45 minutes. Nicotinic acid was able to
release PGD2 with an effector concentration for half-
maximum response (EC50) of 145 mM. This release was
abolished in the presence of 10 mM indomethacin, a
cyclooxygenase inhibitor. Nicotinic acid (1 mM) elicited
PGD2 release from whole skin punches in a time-dependent
manner, with PGD2 release becoming significantly different
from control as early as 15 minutes post-incubation (Figure
5b). PGD2 release was significantly different (Po0.01) from
all untreated samples at times greater than 25 minutes.
Standard incubation time was thus fixed to 30 minutes for
all subsequent experiments.
Cultured mouse mixed epidermal cells were assayed for
PGD2 release following nicotinic acid stimulation and
consistently showed results similar to those obtained with
ear skin punches (data not shown) with a average EC50 of
3737160 mM (N¼ 10). Nicotinamide was used as a negative
control and failed to cause significant PGD2 release. Because
we observed substantial differences in the magnitude of the
response to nicotinic acid between preparations, and
experienced difficulty isolating a large number of pure mouse
epidermal Langerhans cells, we sought a more suitable
Langerhans cell model.
hLCs release PGD2 in response to nicotinic acid
hLCs, generated by in vitro differentiation as described above
(hLC-L) were tested for their ability to release PGD2 in
a b c d
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Figure 3. Immunostaining of cultured CD34þ -derived hLCs. (a) Phase contrast micrograph of cells fixed in methanol. (b) Corresponding fluorescence staining
with anti-GPR109-COOH Abs. (c–j) Phase contrast and corresponding anti-GPR109-COOH and 40,6 diamidino-2-phenylindole (DAPI) fluorescence staining
of enlarged boxed cells 1 and 2 from (a, b). (g) Fluorescence staining with anti-CD1a Abs and DAPI. (h) Fluorescence staining with anti-langerin Abs.
(i) Fluorescence staining with anti-PGD2 synthase Abs. (j, k) Negative control staining with only secondary anti-mouse (j) or anti-rabbit (k) IgG. Bar¼10 mm
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response to nicotinic acid (Figure 6a). Nicotinic acid did not
induce detectable PGD2 release in naive cells; however, it
elicited a significant increase in cells pretreated overnight
with 75 ng/ml IFNg. As observed with mouse epidermal cells,
the concentration of nicotinic acid required to stimulate
PGD2 release from hLC-Ls was high (between 100 mm and
10 mM), with an average EC50 of 1.2 mM70.7 (N¼ 22).
Nonspecific background, that is, PGD2 measured in the
presence of indomethacin, was also higher after IFNg
pretreatment. IFNg-treated hLC-Ls proved remarkably con-
sistent with regard to PGD2 release in response to nicotinic
acid, with an average EC50 of 3.3171.45 pg PGD2 released
per 1000 hLC-Ls at the maximal 10 mM nicotinic acid
stimulation.
To ascertain whether the nicotinic acid-stimulated PGD2
release was indeed mediated via a nicotinic acid–GPR109A
interaction, we tested Acifran, a structurally distinct
GPR109A agonist. Acifran is able to stimulate guanosine
triphosphategS binding on membranes prepared from CHO
cells transfected with GPR109A with an average EC50 10-fold
higher than nicotinic acid (1127 vs 104 nM; Taggart et al.,
2005). Figure 7a shows that Acifran induced PGD2 release in
IFNg-treated hLC-L in a very similar manner to nicotinic
acid, with an EC50 of 786 vs 831mM for nicotinic acid.
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Figure 4. IFNc stimulates GPR109A expression in CD34þ -derived hLCs.
(a) Quantitative RT-PCR analysis was performed in triplicate using total RNA
isolated from hLC-Ls treated overnight with vehicle or IFNg (75 ng/ml).
Data represent the ratio of the means of GPR109A mRNA and S9 ribosomal
protein mRNA7SE of the mean. (b) Surface expression of GPR109A. hLC-Ls
treated with vehicle (blue line) or INFg (red line) were analyzed by
flow cytometry using rabbit anti-GPR109-NH2 polyclonal Ab NLS-179.
(c) Immunofluorescence staining of GPR109 on the plasma membrane
of hLC-Ls treated with vehicle (left panel) or INFg (right panel) using
rabbit anti-GPR109-NH2 polyclonal Ab NLS-179. Bar¼ 25 mm.
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Figure 5. Nicotinic acid induces PGD2 release in mouse skin ex vivo. Dorsal ear halves were prepared as described and exposed to nicotinic acid for the
indicated times. At the end of the incubation, medium was collected for PGD2 determination. Results shown are the mean7SD of quadruplicate determinations
from one representative experiment replicated three times with similar results. (a) Dose–response relationship after 45 minutes incubation (’, nicotinic acid;
&, nicotinic acidþ10 mM indomethacin). Data were analyzed using analysis of variance followed by Dunnett’s post hoc test: *Po0.05; **Po0.01 when
compared with control. (b) Time course (’, nicotinic acid 1 mM; &, Vehicle) *Po0.05, **Po0.01 when compared to all vehicle time points.
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Figure 6. PGD2 release from CD34þ -derived hLCs. Nicotinic acid
promotes release of PGD2 in IFNg-stimulated hLC-Ls. Human LC-Ls were
cultured overnight in the presence or absence of 75 ng/ml IFNg, collected,
and incubated for 30 minutes (25k cells/well) in the presence of increasing
concentrations of nicotinic acid7indomethacin. Medium was collected for
PGD2 determination. (K, nicotinic acid; J, nicotinic acidþ indomethacin;
’, nicotinic acidþ IFNg; &, nicotinic acidþ IFNgþ indomethacin). Results
shown are the mean7SD of triplicate determinations from one representative
experiment replicated at least three times with similar results. Analysis of
variance followed by Dunnett’s post hoc test: **Po0.01 when compared
to control.
www.jidonline.org 2641
D Maciejewski-Lenoir et al.
Niacin Releases PGD2 in Langerhans Cells
Acifran-induced PGD2 release was inhibited by 10mM indo-
methacin. We also tested structural analogs of nicotinic acid
that do not interact with GPR109A. Isonicotinic acid, an isomer
of nicotinic acid differing in the position of the carboxylic acid
(in the para-position of the pyridine ring instead of the meta
position) has a very low affinity for GPR109A (EC504100mM).
Isonicotinic acid as well as acetic acid were both assayed for
PGD2 release in IFNg-treated hLC-Ls. Figure 7b shows that
nicotinic acid significantly stimulated PGD2 release, whereas
isonicotinic acid and acetic acid did not.
DISCUSSION
Our results demonstrate that Langerhans cells are able to
release PGD2 in response to nicotinic acid treatment. The
released PGD2 activates vascular cells and causes cutaneous
vasodilatation. Although GPR109A expression is widely
distributed in a variety of immune cells and adipocytes, we
only observed PGD2 release in response to nicotinic acid in
skin explants or hLC-Ls. Release of PGD2 occurred within
15 minutes after nicotinic acid addition in skin explants.
There is a discrepancy between the lag time needed for
nicotinic acid to significantly release PGD2 in vitro (15 min-
utes), and cutaneous vasodilation in vivo (3–4 minutes; Benyo
et al., 2005). Such difference might be due to inherent
properties of cultured Langerhans cells or differences
between the sensitivity of both assays. The ability of Acifran,
a structurally distinct GPR109A agonist, to release PGD2,
coupled with the absence of PGD2 release obtained with
various negative controls (nicotinamide, isonicotinic acid,
acetic acid) strongly suggests that nicotinic acid mediates its
flushing effect through interaction with GPR109A. This is
consistent with a recent report from Benyo et al. (2005) who
demonstrated that mice lacking PUMA-G, the murine ortho-
log of GPR109A, did not show cutaneous ear vasodilation in
response to nicotinic acid. Additionally, transplantation of
wild-type bone marrow into irradiated PUMA-G-deficient
mice restored the nicotinic acid-induced flushing response,
indicating that flushing in response to nicotinic acid is
mediated through a bone marrow-derived cell.
Whereas the primers used to detect GPR109A mRNA in
human tissue and cells were selective for this receptor and
did not recognize GPR109B, the Abs we used for the
immunocytochemical characterization did recognize both
GPR109A and B. The need of a very high concentration of
nicotinic acid to release PGD2 in Langerhans cells could be
explained by an interaction with GPR109B, the low affinity
nicotinic acid receptor. However, Acifran, a ligand for both
GPR109A and B (EC50: 1.17mM for GPR109A, 4.11mM for
GPR109B) was no more potent than nicotinic acid in causing
the release of PGD2 in Langerhans cells. Selective tools
for both GPR109A and B will be required to ascertain
the possible involvement of GPR109B in the flushing
mechanism.
The results obtained with in vitro skin explants, skin cells,
and hLC-L correspond to the nicotinic acid-induced flushing
in humans: the response occurs rapidly, is dose-dependent,
can be blocked by a cyclooxygenase inhibitor, and is
localized to the skin. Morrow et al. (1992) have demonstrated
that after nicotinic acid oral administration, high concentra-
tions of PGD2 are present in the venous circulation draining
skin, but not in the arterial circulation, indicating a local
release from the skin. Langerhans cells are indeed uniquely
distributed in the skin. They have been shown to express
particularly large amounts of hematopoietic PGD2 synthase,
(Ujihara et al., 1988) suggesting that they have a robust PGD2
biosynthetic capacity. Blood cells such as neutrophils and, to
a lesser degree, monocytes also express GPR109A, but these
cells failed to release PGD2 in response to nicotinic acid in
our experiments. Together, these results suggest that Langer-
hans cells are a key mediator of nicotinic acid-stimulated
flushing.
High concentrations (about 103–104-fold higher than
nicotinic acid-induced guanosine triphosphategS stimu-
lation (EC50¼ 100 nM)) of nicotinic acid are needed to elicit
release of PGD2 in vitro from whole-skin explants, dissociated
mouse epidermal cells, or hLCs. Whereas Langerhans cells
require nicotinic acid concentrations higher than 500mM
(EC50B1 mM) to release PGD2, the concentration of nicotinic
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Figure 7. Selectivity of nicotinic acid response. Human LC-Ls were stimulated overnight with 75 ng/ml IFNg, collected, and incubated for 30 minutes (25k
cells/well) in the presence of indicated compounds. Medium was collected for PGD2 determination. (a) Comparison between nicotinic acid (’) and Acifran (m).
Open symbols represent corresponding treatments in the presence of indomethacin. Results shown are the mean7SD of triplicate determinations from
one representative experiment replicated at least three times with similar results. **Po0.01 when compared to control. (b) Comparison between nicotinic
acid (’) acetic acid (K), and isonicotinic acid (E). Open symbols represent corresponding treatments in the presence of indomethacin. **Po0.01 when
compared to corresponding concentration of other compound.
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acid needed to lower free fatty acids in cultured adipocytes is
in the micromolar range (data not shown). Although there
is considerable individual variability in the intensity of the
flushing reaction after nicotinic acid ingestion, a study by
Wilkin et al. (1982) shows that normal subjects (N¼25)
showed significant malar thermal circulation changes after
oral doses of nicotinic acid as low as 2.86 mg/kg, correspond-
ing to 100–200 mg nicotinic acid ingestion. Nicotinic acid
plasma levels used to achieve therapeutic efficacy reach peak
levels of approximately 30 mg/ml (243 mM) within 30 minutes
after 1 g nicotinic acid ingestion (Carlson et al., 1968) and
this concentration does not induce PGD2 release in
IFNg-stimulated hLC-L. The mechanism of nicotinic acid-
induced flushing is not completely understood. The sensitiv-
ity of the mechanism to cyclooxygenase inhibitors suggests
the involvement of prostanoid-dependent signaling, and
nicotinic acid could act by stimulating the activity of PLA2,
cyclooxygenase, or hematopoietic PGD2 synthase. Schizo-
phrenic patients have a reduced nicotinic acid skin-flush
response and it has been suggested that this is due to reduced
levels of arachidonic acid (Peet, 2003). In our different in
vitro models, skin explants were 10-fold more sensitive to
nicotinic acid than cultured hLC-L. It is possible that isolated
cells are not appropriately activated, or primed, and do no
have the prostaglandin synthetic capacity of skin resident
Langerhans cells. Further studies including activation
of PLA2, release of arachidonic acid, and activation of
hematopoeitic PGD2 synthase need to be performed
to understand why such high concentrations of nicotinic
acid are required for PGD2 release in hLC-Ls and whether
a priming agent or pathway is required.
IFNg, a pleiotropic cytokine playing a fundamental role in
immune defense and macrophage activation, induces
GPR109A mRNA expression and GPR109 receptor expres-
sion on the cell membrane of hLC-Ls. Cells isolated from the
epidermis and cultured overnight are able to release PGD2
upon nicotinic acid stimulation without pretreatment with
IFNg, whereas naive CD34þ cells need to be pretreated with
IFNg to become responsive to nicotinic acid. Our experi-
ments with skin explants, cultured epidermal cells, and IFNg-
activated hLC-Ls show that these cells have the capacity to
respond to nicotinic acid by releasing PGD2, whereas other
cells expressing GPR109A, such as adipocytes, monocytes, or
neutrophils, apparently do not. Langerhans cells are closely
related to macrophages as both cells are offspring of the same
CD34þ hematopoietic progenitor cell and represent term-
inal stages of monocyte differentiation (Palucka et al., 1998).
Further studies with activated primary macrophages might
also show release of PGD2 in response to nicotinic acid, as
IFNg has been shown to increase the expression of GPR109A
on these cells (Schaub et al., 2001).
The function of GPR109A on neutrophils and monocytes
is still unclear. GPR109A expression is particularly abundant
in neutrophils. GPR109A expression is upregulated by GM-
CSF (Yousefi et al., 2000) in neutrophils, whereas IFNg
increases GPR109A in monocytes/macrophages (Schaub
et al., 2001). Our experiments showed that nicotinic acid
was not able to elicit measurable PGD2 release from
neutrophils, monocytes, or macrophage cell lines, indicating
that these cells may mediate another type of response to the
nicotinic acid–GPR109A interaction. Rubic et al. (2004)
showed that in monocytoid cells, nicotinic acid increases
transcription of peroxisome proliferator-activated receptorg,
CD36, and ABCA1, key players in the reverse cholesterol
transport pathway. It is thus possible that the beneficial
therapeutic effect derived from nicotinic acid treatment may
be mediated through interaction with GPR109A expressed on
monocytes/macrophages and/or adipocytes, whereas the
toxic flushing side effect is mediated by skin localized
Langerhans cells. Further studies targeting the effect of a
nicotinic acid–GPR109A interaction in immune cell types
might shed some light on its potential therapeutic mechanism
of action.
MATERIALS AND METHODS
Nicotinic acid, Acifran, and isonicotinic acid were obtained from
Sigma-Aldrich (St Louis, MO). Recombinant GM-CSF and IFNg were
obtained from R&D systems (Minneapolis, MN). The following Abs
were used for immunostaining: rabbit polyclonal anti-mouse CD1
(M-276, Santa Cruz biotechnology Inc., Santa Cruz, CA), mouse
anti-keratin epithelial monoclonal Ab AE3 (Chemicon, Temecula,
CA), mouse monoclonal anti-human CD1a (clone 010, Dako-
Cytomation, Carpentaria, CA), mouse monoclonal anti-langerin
(DCGM4, Beckman Coulter Inc., Miami, FL), rabbit polyclonal
anti-hematopoietic PGD2 synthase (Cayman, Ann Harbor, MI),
rabbit polyclonal anti-GPR109-NH2 Ab NLS-179 (Novus Biochem-
icals Inc., Littleton, CO). A polyclonal Ab directed against a peptide
(NH2-CLQRKMTGEPDNNRSTSVE LTG-CONH2; Synpep, Dublin,
CA) located in the intracellular C-terminus of GPR109A was raised
in rabbit and affinity-purified by Covance (Denver, PA). It was further
characterized using immunohistochemistry and Western blot on
HEK cells transfected with mouse or human GPR109A or GPR109B
(HM74, the low affinity nicotinic acid receptor). This Ab (further
referred as anti-GPR109-COOH) recognized mouse GPR109A (the
peptide sequence between human and mouse differs by only three
amino acids), and both GPR109A and B. It was routinely used at a
concentration of 5–10 mg/ml. Specificity was assessed using cells
transfected with the vector alone, other non-related G-protein-
coupled receptors, or preincubation of anti-GPR109-COOH Ab for
30 minutes with a 10-fold molar excess of the corresponding
immunogenic peptide.
Male C7Bl/6 mice (7–8 weeks old) were purchased from Harlan
(Indianapolis, IN). Human skin was obtained though Arena’s
biorepository facility in collaboration with University of California,
San Diego medical center. All procedures were approved by the
local BioMed Institutional Review Board and were conducted
according to the Declaration of Helsinki Principles. The skin was
collected from recently deceased (approximately 12 hours postmor-
tem) human donors and kept in ice-cold RPMI supplemented with
10% fetal bovine serum. Separation of dermis and epidermis was
performed according to Pena-Cruz et al. (2001).
The human epidermoid carcinoma cell line A-431 and mouse
macrophage cell line RAW 264.7 were obtained from ATCC
(Manassas, VA). Human primary cells (normal human dendritic
cells, human dermal microvascular endothelial cells, normal human
dermal fibroblasts, normal human epidermal keratinocytes, and
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bronchial smooth muscle cells) were obtained from Cambrex
(Walkersville, MD). Human differentiated adipocytes were obtained
from Zen Bio (Research Triangle Park, NC). Pure populations of
CD34þ progenitor cells derived from umbilical cord blood
(Ayehunie et al., 2003) and matured to generate a Langerhans
cell-like phenotype expressing CD1a, MHC class II, and Birbeck
granules, a key ultrastructural marker of Langerhans cells (Valladeau
et al., 2000) were obtained from MatTek Corporation (Ashland, MA).
These cells (referred as hLC-L in the text) were cultured according to
the manufacturer’s protocol.
Mouse ear punches
Mice were killed via CO2 asphyxiation followed by cervical
dislocation, whole ears were removed and stored overnight in ice-
cold RPMI supplemented with 10% fetal bovine serum and 10 mg/ml
gentamycin (Invitrogen, Carlsbad, CA). The next morning, ears were
pulled apart into ventral and dorsal halves and 6 mm punches were
cut out. All punches were then incubated at 371C in RPMI
supplemented with 10% fetal bovine serum for 90 minutes before
stimulation with nicotinic acid.
Mouse mixed epidermal cell culture
Mixed mouse epidermal cell cultures were established according to
a modification of Koyama et al. (1990). Briefly, mice were killed via
CO2 asphyxiation. The trunk of the mouse was shaved with electric
clippers and the remaining hair was removed with a 2 minutes
application of calcium thioglycolate cream (lotion hair remover,
Sally Hansens, Uniondale, NY). Skin was washed with a large
amount of tap water and dissected out. All skin samples were
incubated overnight in an ice-cold 1:1 mixture of dispase II (2.4 U/
ml, Roche, Indianapolis, IN) and RPMI supplemented with 10% fetal
bovine serum. Half of the digestion mixture was then replaced with
fresh dispase II and incubated for an additional 4 hours at 371C under
rotation (150 r.p.m., Innova 4080 shaker, New Brunswick Inc.,
Edison, NJ). The epidermis was gently scraped off whole-skin
samples using curved forceps, and these cells were dissociated
with repeated pipetting, washed and plated at a density of
1.5 106 cells/ml in RPMI supplemented with 10% fetal bovine
serum supplemented with 1 ng/ml GM-CSF. The cell suspension was
incubated at 371C overnight before use.
Microarray analysis
Total RNA from normal human tissues of multiple donors was
purchased from various commercial sources. The quality of total
RNA was assessed by the visible absence of significant 28S and 18S
band degradation using an Agilent 2100 bioanalyzer and by
spectrophotometry (ratio 28S:18S41.2). Total RNA was analyzed
with high-density oligonucleotide microarrays as described pre-
viously (Hakak et al., 2003) using the Affymetrix (Santa Clara, CA)
GeneChip technology. Each total RNA sample was profiled in
duplicate and data analyzed using GeneChip software MAS 5.0.
Specificity of the GPR109A microarray probes was tested using HEK
cells transfected with either GPR109A or the closely related human
gene GPR109B. Whereas the probes designed to monitor GPR109A
detected a signal in the HEK cells transfected with GPR109A
plasmid, no signal was observed in HEK cells transfected with
GPR109B or with the vector alone. Results are expressed as relative
expression levels, which is a measure of the signal intensity obtained
by the hybridization with probes representing GPR109A on the
microarray.
Quantitative RT-PCR
GPR109A expression levels in hLCs were assessed by real-time RT-
PCR TaqMans analysis using the ABI Prism 7900 Sequence Detector
Systems (PE Applied Biosystems, Foster City, CA). For cDNA
synthesis, 1.5 mg total RNA (from the same samples analyzed by
microarray analysis) were reverse transcribed using TaqMans RT
reagents (PE Applied Biosystems). The primer design software Primer
ExpressTM (PE Applied Biosystems) was used to design TaqMans
primers and probes specific for GPR109A (forward primer: 50-
GCCCTTCCTGATGGACAAC-30; reverse primer: 50-TAGCCAACAT
GAAGAGCATC-30; probe: 50-AACTTCCAGTCCCAACGCCTCACA-
30). PCR assays were performed using 300 nM of each primer and
200 nM probe at an annealing temperature of 651C. These primers
did not recognize GPR109B when assayed with RNA isolated from
HEK cells transfected with GPR109B. A cytomegalovirus plasmid
containing the open-reading frame of GPR109A was used for
standard curves. Human S9 ribosomal protein transcript levels were
also measured as an internal control. All PCR assays were performed
in triplicate. Results are represented as the ratio of the mean and
standard deviation of replicate measurements of GPR109A and S9
ribosomal protein (calculated as pg).
For some TaqMan studies, Cybergreen dye was used to allow for
quantitation. In these studies, total RNA from mouse and human
epidermal or dermal cells was isolated using RNAzol (Tel-Test,
Friendswood, TX) according to the manufacturer’s protocol. RT-PCR
was carried out in a 20 ml reaction mixture prepared with
1 Cybergreen mix, 500 ng primers, and 1.5mg of cDNA. To
obtain a calibration curve, we amplified a known amount of human
or mouse genomic DNA in the same manner as the samples. Data
presented represent the amount of signal obtained from tissue
samples divided by the signal obtained from the genomic control
and is expressed as relative units.
Immunohistochemistry
Non-adherent mouse mixed epidermal cells enriched with Langer-
hans cells or Langerhans cells derived from CD34 cells (hLC-Ls)
were suspended in phosphate-buffered saline (PBS) at a dilution of
1 106 cells/ml. Aliquots (50 ml) of each cell suspension were
centrifuged (400 g, 2 minutes) onto glass slides (cytospin). Cells
were fixed for 5 minutes in cold (201C) methanol, air dried, and
washed in PBS. Fixed cells were blocked for 1 hour in PBS
containing 2% BSA (fraction V) and 0.1% Triton X-100 (blocking
buffer), and then incubated for 1 hour with the indicated primary Abs
diluted in blocking buffer. After three consecutive washes with PBS,
they were further incubated for 30 minutes with goat anti-mouse or
anti-rabbit IgG Abs labeled with fluorochrome (Alexa 488 or 594,
Molecular Probe Inc., Eugene, OR) diluted 1:1,000 in blocking
buffer. Controls included staining with the secondary Ab alone,
staining other cell types, or using a 10-fold molar excess of the
corresponding immunogenic peptide.
For the detection of GPR109A localized on the plasma
membrane of Langerhans cells, control hLC-L cells or hLC-L cells
treated overnight with 100 ng/ml IFNg were harvested, washed three
times with PBS supplemented with 0.1% normal goat serum and
fixed with 3.7% formaldehyde for 10 minutes at room temperature.
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After blocking for 10 minutes with 4% normal goat serum in PBS,
cells were incubated with 30 mg/ml of anti-GPR109 rabbit polyclonal
Ab NLS179 (Novus Biologicals; this Ab recognizes both GPR109A
and GPR109B) for 30 minutes at 371C. Cells were washed four times
with PBS, incubated for 30 minutes at 371C and fixed again in 3.7%
formaldehyde. After blocking with 4% normal goat serum in PBS,
cells were incubated with FITC-conjugated donkey anti-rabbit Ab for
30 minutes at 371C. Cells were washed, incubated, and fixed as
processed for the first Ab. Finally, cells were either processed for
immunofluorescence microscopy by mounting them between cover-
slip and glass slides, or analyzed by FACS. Immunofluorescence
analysis was performed on a Leica DMRA2 microscope equipped
with a Retiga EX CCD camera. To compare GPR109 staining on
treated and untreated cells, images were taken for the same time
interval with all image acquisition parameters fixed. FACS analysis
was performed on FACSScan flow cytometer (Becton-Dickinson,
Franklin Lakes, NJ).
Western blot analysis
Lysate samples were prepared from mouse mixed epidermal cells
and HEK 293 cells transfected using lipofectamine (Invitrogen) with
an expression vector bearing GPR109A under the control of
cytomegalovirus promoter or the identical plasmid without a
GPR109A insert. Cells were scraped off, lysed for 1 hour at 371C
in lysis buffer (10 mM Tris HCl (pH 8.0), 10 mM NaCl, 3 mM MgCl2,
0.5% Nonidet P-40, protease inhibitor cocktail III, 2 mM sodium
orthovanadate, DNAse 1 U/ml) and centrifuged at 4,000 r.p.m. for
10 minutes. The protein concentration of each lysate was determined
using the Bradford method (Bio-Rad, Hercules, CA). A portion
(20 mg) of protein lysate was mixed with SDS-PAGE gel-loading
buffer (LDS buffer from NuPage, Invitrogen) heated for 5 minutes at
1001C and cooled on ice. Samples were loaded on 4–10% Bis-Tris
gradient gels (NuPage). After separation, the proteins were trans-
ferred to nitrocellulose via standard NuPage Western blot protocol.
The resulting blot was blocked for 1 hour in PBS containing 3% BSA
and 0.05% Tween 20, then incubated for 1 hour at room temperature
with approximately 1mg/ml anti-GPR109A-COOH Ab. After wash-
ing in Tris-buffered saline containing 0.05% Tween 20, the blot was
treated with enhanced chemiluminescence plus Western blotting
Detection system reagents (Amersham Biosciences, Piscataway, NJ)
according to the manufacturer’s protocol and exposed to X-ray film
for various times.
PGD2 assay
The PGD2 content of culture medium was assayed by ELISA
(Cayman, Ann Arbor, MI) according to the manufacturer’s instruc-
tions and optimized as follows. Briefly, cells were collected and
re-suspended in RPMI at the desired density. For the assay, 50 ml of
cell suspension was added to 450 ml pre-warmed (371C) RPMI
containing nicotinic acid or other compounds at various concentra-
tions adjusted to pH 7.0 with NaOH. The cells were then incubated
at 371C, 5% CO2 for 30 minutes. The medium of each well was
collected, briefly spun at 400 g to remove cells or debris and the
released PGD2 was extracted by addition of 17.5 ml of 1 N HCl and
1.5 ml ethyl acetate. After mixing, the organic phase was collected
and evaporated in a speedvac. The dry residue was re-suspended
into 100ml ELISA buffer and derivatized into PGD2-MOX by
incubating for 30 minutes at 601C after the addition of 100ml MOX
reagent. The derivatized PGD2-MOX was then assayed by ELISA
according to the Cayman Kit instructions. Control experiments
in which PGD2 was added into media showed over 95% recovery.
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